STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (STO:ORX) confirms the announcement made by ProStrakan Group plc (LSE:PSK), Orexo’s partner for Abstral® in Europe and North America, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Marketing Authorisation for Abstral (for breakthrough cancer pain). As a result of the approval, Orexo will receive a milestone payment of USD 1 million.
